company background image
OXB

Oxford BiomedicaLSE:OXB Stock Report

Market Cap

UK£1.2b

7D

-3.8%

1Y

56.8%

Updated

29 Nov, 2021

Data

Company Financials +
OXB fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance3/6
Financial Health6/6
Dividends0/6

OXB Stock Overview

Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various diseases in Europe and internationally.

Oxford Biomedica Competitors

Pharming Group

ENXTAM:PHARM

€462.7m

Price History & Performance

Summary of all time highs, changes and price drops for Oxford Biomedica
Historical stock prices
Current Share PriceUK£13.56
52 Week HighUK£16.78
52 Week LowUK£8.10
Beta0.74
1 Month Change-10.91%
3 Month Change-8.50%
1 Year Change56.76%
3 Year Change89.65%
5 Year Change604.42%
Change since IPO-46.30%

Recent News & Updates

Shareholder Returns

OXBGB BiotechsGB Market
7D-3.8%-2.4%-1.9%
1Y56.8%24.4%13.8%

Return vs Industry: OXB exceeded the UK Biotechs industry which returned 24.6% over the past year.

Return vs Market: OXB exceeded the UK Market which returned 11.6% over the past year.

Price Volatility

Is OXB's price volatile compared to industry and market?
OXB volatility
OXB Average Weekly Movement5.6%
Biotechs Industry Average Movement5.9%
Market Average Movement4.9%
10% most volatile stocks in GB Market9.7%
10% least volatile stocks in GB Market2.6%

Stable Share Price: OXB is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: OXB's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1995744John Dawsonhttps://www.oxb.com

Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various diseases in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes.

Oxford Biomedica Fundamentals Summary

How do Oxford Biomedica's earnings and revenue compare to its market cap?
OXB fundamental statistics
Market CapUK£1.17b
Earnings (TTM)UK£18.50m
Revenue (TTM)UK£135.00m

63.1x

P/E Ratio

8.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
OXB income statement (TTM)
RevenueUK£135.00m
Cost of RevenueUK£69.71m
Gross ProfitUK£65.29m
ExpensesUK£46.79m
EarningsUK£18.50m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.21
Gross Margin48.36%
Net Profit Margin13.71%
Debt/Equity Ratio0%

How did OXB perform over the long term?

See historical performance and comparison

Valuation

Is Oxford Biomedica undervalued compared to its fair value and its price relative to the market?

63.09x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: OXB (£13.56) is trading above our estimate of fair value (£1.33)

Significantly Below Fair Value: OXB is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: OXB's PE Ratio (63.1x) is in line with the UK Biotechs industry average.

PE vs Market: OXB is poor value based on its PE Ratio (63.1x) compared to the UK market (19.2x).


Price to Earnings Growth Ratio

PEG Ratio: OXB's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: OXB is overvalued based on its PB Ratio (8.8x) compared to the GB Biotechs industry average (6.3x).


Future Growth

How is Oxford Biomedica forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

-12.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OXB's earnings are forecast to decline over the next 3 years (-12.8% per year).

Earnings vs Market: OXB's earnings are forecast to decline over the next 3 years (-12.8% per year).

High Growth Earnings: OXB's earnings are forecast to decline over the next 3 years.

Revenue vs Market: OXB's revenue is expected to decline over the next 3 years (-4.2% per year).

High Growth Revenue: OXB's revenue is forecast to decline over the next 3 years (-4.2% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: OXB's Return on Equity is forecast to be low in 3 years time (4.6%).


Past Performance

How has Oxford Biomedica performed over the past 5 years?

28.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OXB has high quality earnings.

Growing Profit Margin: OXB became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: OXB has become profitable over the past 5 years, growing earnings by 28.9% per year.

Accelerating Growth: OXB has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: OXB has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (50.7%).


Return on Equity

High ROE: OXB's Return on Equity (14%) is considered low.


Financial Health

How is Oxford Biomedica's financial position?


Financial Position Analysis

Short Term Liabilities: OXB's short term assets (£123.9M) exceed its short term liabilities (£47.3M).

Long Term Liabilities: OXB's short term assets (£123.9M) exceed its long term liabilities (£17.8M).


Debt to Equity History and Analysis

Debt Level: OXB is debt free.

Reducing Debt: OXB has no debt compared to 5 years ago when its debt to equity ratio was 336.6%.

Debt Coverage: OXB has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: OXB has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Oxford Biomedica current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OXB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OXB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OXB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OXB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OXB's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.4yrs

Average management tenure


CEO

John Dawson (61 yo)

13.08yrs

Tenure

UK£1,258,000

Compensation

Mr. John Dawson has been the Chief Executive Officer of Oxford BioMedica PLC since October 13, 2008. Mr. Dawson has broad experience in European commercial activities, finance and in mergers and acquisitio...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD1.67M) is about average for companies of similar size in the UK market ($USD1.53M).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: OXB's management team is considered experienced (3.4 years average tenure).


Board Members

Experienced Board: OXB's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: OXB insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.7%.


Top Shareholders

Company Information

Oxford Biomedica plc's employee growth, exchange listings and data sources


Key Information

  • Name: Oxford Biomedica plc
  • Ticker: OXB
  • Exchange: LSE
  • Founded: 1995
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£1.167b
  • Shares outstanding: 86.09m
  • Website: https://www.oxb.com

Number of Employees


Location

  • Oxford Biomedica plc
  • Windrush Court
  • Transport Way
  • Oxford
  • Oxfordshire
  • OX4 6LT
  • United Kingdom

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/29 22:53
End of Day Share Price2021/11/29 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.